Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice

Figure 1

(a) Oral glucose tolerance test in db/db mice treated with none, ipragliflozin, alogliptin, ipragliflozin plus alogliptin (combination). versus control (A); versus alogliptin (B). (b) The area under the blood glucose curve for OGTTs. , ^‡. (c) Foam cell formation of peritoneal macrophages in db/db mice., ^§. (d) Correlation between macrophage foam cell formation and hemoglobin A1c (HbA1c) levels in db/db mice. The line indicates the correlation curves for the control and ipragliflozin groups.

(a)

(b)

(c)

(d)